Abstract
One of the main challenges in oncology today has become to distinguish accurately between those patients who need adjuvant treatment and those who do not. This, together with the identification of the best type of therapy for the individual patient and the development of drugs targeting specific characteristics of tumour cells, are the goals of treatment tailoring or personalized medicine. The MINDACT trial (Microarray In Node negative Disease may Avoid ChemoTherapy) was recently launched with the aim of prospectively validating the superior performance of a new prognostic RNA-based tool--the Amsterdam 70-gene profiler MammaPrint, in order to implement its use in clinical practice later on. This manuscript shortly reviews the rational, design and logistics of MINDACT.